In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1125-1134

  Uckun, Fatih M ^a   Narla, Rama Krishna ^a   Zeren, Tamer ^b   Yanishevski, Yuri ^c   Myers, Dorothea E ^a   Waurzyniak, Barbara ^a   Ek, Onur ^b   Schneider, Elizabeth ^a   Messinger, Yoav ^b   Chelstrom, Lisa M ^a   Gunther, Roland ^b   Evans, William ^c  

^a Department of Genetics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SCID MOUSE; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; GENISTEIN; HUMANS; LIVER; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, SCID; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 14444272510     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wood, W. C. Progress from clinical trials on breast cancer. Cancer (Phila.), 74: 2606-2609, 1994.
2. Bonadonna, G., Zambetti, M., and Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. J. Am. Med. Assoc., 273: 542-547, 1995.
3. Ingle, J. N., Foley, J. F., Mailliard, J. A., Krook, J. E., Hartmann, L. C., Jung, S. H., Veeder, M. H., Gesme, D. H., Jr., Hatfield, A. K., and Goldberg, R. M. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer (Phila.), 73: 2337-2343, 1994.
4. Somlo, G., Doroshow, J. H., Forman, S. H., Leong, L. A., Margolin, K. A., Morgan, R. J., Jr., Raschoko, J. W., Akkman, S. A., Ahn, C., and Nagasawa, S. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 1678-1685, 1994.
5. Abrams, J. S., Moore, T. D., and Friedman, M. New chemotherapeutic agents for breast cancer. Cancer (Phila.), 84: 1164-1176, 1994.
6. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
7. George-Nacimento, C., Gyenes, A., Halloran, S. M., Merryweather, J., Valenzuela, P., Steimer, K. S., Masiarz, F. R., and Randolph, A. Characterization of recombinant human epidermal growth factor produced in yeast. Biochemistry, 27: 797-802, 1988.
8. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev., 12: 255-274, 1993.
9. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.) Biologic Therapy of Cancer: Principles and Practice, pp. 607-623. Philadelphia, PA: J. B. Lippincott Company, 1995.
10. Toi, M., Osaki, A., Yamada, H., and Toge, T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer, 27: 977-980, 1991.
11. Chrysogelos, S. A, and Dickson, R. B. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res. Treat., 29: 29-40, 1994.
12. Flx, S. B. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
13. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
14. Wright, J. D., Reuter, C. W., and Weber, M. J. An incomplete program of cellular tyrosine phosphorylations by kinase-defective epidermal growth factor receptors. J. Biol. Chem., 270: 12085-12093, 1995.
15. Broome, M. A., and Hunter, T. Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. J. Biol. Chem., 271: 16798-16806, 1996.
16. Muthuswamy, S. K. Mammary tumors expressing the neu protooncogene possess elevated cSrc tyrosine kinase activity. Mol. Cell. Biol., 14: 735-743, 1994.
17. Ottenhoff-Kalff, A. K., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., and Staal, G. E. Characterization of protein tyrosine kinases from human breast cancer: involvement of the cSrc oncogene product. Cancer Res., 52: 4773-4778, 1992.
18. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Tuel-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
19. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
20. Waurzyniak, B., Schneider, E. A., Tumer, N., Yanishevski, Y., Gunther, R., Chelstrom, L. M., Wendorf, H., Myers, D. E., Irvin, J. D., Messinger, Y., Ek, O., Zeren, T., Chandan-Langlie, M., Evans, W., and Uckun, F. M. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res., 3: 881-890, 1997.
21. Uckun, F. M., Kazimiera, J. G-P., Kersey, J. H., Houston, L., and Vallera, D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med., 163: 347-368, 1986.
22. Gerlowski, L. E., and Jain, R. K. Physiologically based pharmacokinetic modelling: principles and applications. J. Pharm. Sci., 72: 1103-1126, 1983.
23. Davies, B., and Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. (NY), 10: 1093-1095, 1993.
24. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed., 9: 115-134, 1979.
25. Kim, D. C., Sugiyama, Y., Satoh, H., Fuwa, T., Iga, T., and Hanano, M. Kinetic analysis of in vivo receptor dependent binding of human epidermal growth factor by rat tissues. J. Pharm. Sci., 77: 200-207, 1988.
26. Kim, D. C., Sugiyama, Y., Fuwa, T., Sakamoto, S., Iga, T., and Hanano, M. Kinetic analysis of the elimination process of human epidermal growth factor in rats. Biochem. Pharmacol., 38: 241-249, 1989.
27. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
28. Fry, D. W., Kraker, A., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
29. Tanaka, S., Okabe, T., Chieda, S., Endo, K., Kanoh, T., Okura, A., and Yosida, E. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase. Jpn. J. Cancer Res., 85: 253-259, 1994.
30. Reddy, K. B., Mangold, G. L., Tandon, A. K., Yoneda, T., Mundy, G. R., Zilberstein, A., and Osborne, C. K. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res., 52: 3636-3641, 1992.
31. Yaish, P., Gazit, A., Gilon, C., and Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Washington DC), 242: 933-935, 1988.
32. Lyall, R. M., Zilberstein, A., Gazit, A., Gilon, C., Levitzki, A., and Schlessinger, J. Tryphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem., 264: 14503-14509, 1989.
33. Scholar, E. M., and Toews, M. L. Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. Cancer Lett., 87: 159-162, 1994.
34. Monti, E., and Sinha, B. C. Antiproliferative effect of genistein and Adriamycin against estrogen dependent and -independent human breast carcinoma cell lines. Anticancer Res., 14: 1221-1226, 1994.
35. Lamartiniere, C. A., Moore, J. B., Brown, N. M., Thompson, R., Hardin, M. J., and Barnes, S. Genistein suppresses mammary cancer in rats. Carcinogenesis (Lond.), 16: 2833-2840, 1995.
36. Murrill, W. B., Brown, N. M., Zhang, J. X., Manzolillo, P. A., Barnes, S., and Lamartiniere, C. A. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis (Lond.), 17: 1451-1457, 1996.
37. Ennis, B. W., Lippman, M. E., and Dickson, R. B. The EGF receptor system as a target for antitumor therapy. Cancer Invest., 9: 553-562, 1991.
38. Harns, A. L. The epidermal growth factor receptor as a target for therapy. Cancer Cells (Cold Spring Harbor), 2: 321-323, 1990.
39. Mendelsohn, J. Epidermal growth factor receptor as a target for therapy with anti-receptor monoclonal antibodies. J. Natl. Cancer Inst. Monogr., 13: 125-131, 1992.
40. Baselga, J., and Mendelsohn, J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 29: 127-138, 1994.
41. Uckun, F. M., Narla, R. K., Jun, X., Zeren, T., Venkatachalam, T., Waddick, K. G., Rostostev, A., and Myers, D. E. Cytotoxic activity of epidermal growth factor-genistein against human breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.